{"gene":"LMO2","run_date":"2026-04-28T18:30:27","timeline":{"discoveries":[{"year":1994,"finding":"LMO2 (RBTN2) is a nuclear protein essential for yolk sac erythropoiesis; homologous recombination knockout in mice causes failure of erythroid development and embryonic lethality around E10.5, establishing its pivotal role in lineage specification.","method":"Homologous recombination knockout in mice, in vitro differentiation of yolk sac tissue, ES cell targeting","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 — clean KO with defined cellular phenotype, replicated across multiple experimental approaches in one study","pmids":["8033210"],"is_preprint":false},{"year":1994,"finding":"LMO2 (RBTN2) forms a complex with TAL1 in the nucleus of erythroid cells; RBTN2 is not phosphorylated while TAL1 is a phosphoprotein; both proteins are coexpressed in erythroid cells and are crucial for erythropoiesis.","method":"Co-immunoprecipitation with anti-RBTN2 and anti-TAL1 antisera in erythroid cells","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — reciprocal Co-IP in native erythroid cells, replicated by multiple labs","pmids":["8078932"],"is_preprint":false},{"year":1995,"finding":"LMO2 (RBTN2) directly interacts in vivo and in vitro with GATA1 and GATA2 zinc-finger transcription factors, as well as with TAL1; mammalian two-hybrid analysis demonstrated a complex involving RBTN2, TAL1, GATA1, and E47, linking three proteins crucial for erythropoiesis.","method":"In vitro pull-down, co-immunoprecipitation, mammalian two-hybrid analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods (in vitro and in vivo), replicated across labs","pmids":["7568177","9209374"],"is_preprint":false},{"year":1996,"finding":"LMO2 and TAL1 proteins form dimers in thymocytes of double-transgenic mice; co-expression of Lmo2 and Tal1 in T cells alters thymocyte development (accumulation of immature T cells) and potentiates T-cell tumor formation approximately 3 months earlier than Lmo2 alone, demonstrating synergistic oncogenic interaction.","method":"Transgenic mouse co-expression, protein dimerization detection in thymocytes, tumor latency comparison","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 — direct protein interaction shown in vivo with clear functional phenotype, strong genetic epistasis","pmids":["8605871"],"is_preprint":false},{"year":1997,"finding":"LMO2 and Ldb1 exist in a stable complex in murine erythroleukemia cells; Ldb1, LMO2, and SCL/E12 can assemble as a multiprotein complex on a consensus SCL binding site; forced expression of Ldb1 or LMO2 in erythroid progenitor cells inhibits cellular maturation, indicating LMO2-Ldb1 complex maintains erythroid precursors in an immature state.","method":"Co-immunoprecipitation, gel shift/EMSA, forced expression in G1ER proerythroblast cells","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — Co-IP plus functional overexpression with defined cellular phenotype, multiple methods","pmids":["9391090"],"is_preprint":false},{"year":1998,"finding":"Lmo2 null ES cells do not contribute to any hematopoietic lineage in adult chimeric mice, demonstrating Lmo2 is necessary for all adult hematopoiesis; reintroduction of Lmo2 expression vector rescues this defect, and the mechanism likely involves interaction with Tal1/Scl.","method":"Chimeric mouse assay with homozygous Lmo2-/- ES cells, rescue by retroviral re-expression","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — genetic loss-of-function with rescue, clear lineage phenotype","pmids":["9520463"],"is_preprint":false},{"year":1998,"finding":"In T cells from Lmo2 transgenic mice, Lmo2 forms an oligomeric DNA-binding complex that recognizes a bipartite motif of two E-box sequences ~10 bp apart; this complex is restricted to immature CD4-CD8- thymocytes and is distinct from the complex found in erythroid cells.","method":"CASTing (cyclic amplification and selection of targets), band shift/EMSA, immunophenotyping","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1-2 — direct DNA-binding complex isolation with sequence specificity, combined with cellular phenotype","pmids":["9707419"],"is_preprint":false},{"year":2000,"finding":"Lmo2 is expressed in vascular endothelium and is required for angiogenic remodeling of the capillary network into mature vasculature but not for de novo vasculogenesis; Lmo2-null ES cells fail to contribute to endothelial cells of large vessel walls after E10, demonstrating a distinct role in angiogenesis.","method":"Chimeric mouse analysis with Lmo2-null ES cells, histological and vascular imaging","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — clean loss-of-function with defined vascular phenotype, replicated in multiple chimeric mice","pmids":["10618416"],"is_preprint":false},{"year":2001,"finding":"In Xenopus, LMO-2 acts synergistically with SCL and GATA-1 to specify hematopoietic mesoderm; co-expression of all three factors leads to ventralized embryos with ectopic blood, and their interaction in a transcriptional complex was demonstrated in vitro.","method":"Xenopus animal cap assay, whole embryo overexpression, in vitro complex assembly","journal":"Development (Cambridge, England)","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis in whole embryo with in vitro complex validation","pmids":["11493549"],"is_preprint":false},{"year":2002,"finding":"Lmo2 is an obligatory regulator of tumor neo-vascularization; Lmo2-null ES cells fail to produce CD31-positive sprouting endothelium in teratocarcinomas in nude mice, while heterozygous cells do, establishing Lmo2 as necessary for tumor angiogenesis.","method":"Teratocarcinoma model in nude mice using Lmo2-null and heterozygous ES cells, CD31 immunostaining","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 — clean loss-of-function in vivo with defined angiogenic phenotype","pmids":["11857074"],"is_preprint":false},{"year":2003,"finding":"The solution structures of LMO2:ldb1 and LMO4:ldb1 complexes were determined by NMR; ldb1-LID binds to the N-terminal LIM domain (LIM1) of LMO2 in an extended conformation, contributing a third strand to a beta-hairpin in LIM1, providing the first molecular definition of LIM-mediated protein-protein interactions.","method":"NMR structure determination (PDB: 1M3V and 1J2O)","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 — NMR structures with functional validation of binding interface","pmids":["12727888"],"is_preprint":false},{"year":2005,"finding":"The LMO2 proximal promoter is regulated by ETS transcription factors Elf1, Fli1, and Ets1, which bind to three conserved ETS sites in vivo; this promoter is sufficient for endothelial expression in vivo but requires additional enhancers for hematopoietic expression.","method":"Chromatin immunoprecipitation, transient/stable transfection, transgenic mouse analysis","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — ChIP in vivo binding plus transgenic validation","pmids":["15994290"],"is_preprint":false},{"year":2006,"finding":"Scl and Lmo2 act together in zebrafish hemangioblast development; scl morphants cannot be rescued by a non-Lmo2-binding form of Scl but can be rescued by non-DNA-binding forms, indicating Scl is tethered to target genes through DNA-binding partners via Lmo2.","method":"Zebrafish morpholino knockdown, rescue with mutant Scl constructs, epistasis analysis","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis with domain-specific rescue experiments","pmids":["17090656"],"is_preprint":false},{"year":2007,"finding":"LMO2 and SCL interact through a conserved interface in the SCL loop and helix 2; this interaction nucleates assembly of SCL complexes on DNA, is required for target gene induction and erythroid/megakaryocytic differentiation, and SCL prevents LMO2 degradation by the proteasome.","method":"Co-immunoprecipitation, domain mutagenesis, in vitro binding assays, proteasome inhibitor experiments","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — mutagenesis of binding interface combined with functional and protein stability assays","pmids":["17878155"],"is_preprint":false},{"year":2008,"finding":"The oncogenic LMO2-Ldb1-TAL1-E12 complex was characterized biophysically; TAL1/E12 bHLH preferentially form heterodimers to which LMO2 binds with high affinity (~10^8 M^-1); the resulting complex forms in the presence or absence of DNA and preferentially binds different E-box sequences.","method":"Biophysical characterization (analytical ultracentrifugation, ITC), EMSA","journal":"Proteins","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution of multiprotein complex with quantitative binding measurements","pmids":["17910069"],"is_preprint":false},{"year":2008,"finding":"An anti-LMO2 single-chain Fv antibody specific for the LIM3-LIM4 region of LMO2 inhibits Lmo2-dependent erythropoiesis and prevents Lmo2-dependent leukemia in a mouse transplantation assay, demonstrating that interference with the LMO2 multiprotein complex disrupts both normal and tumorigenic roles.","method":"Intracellular antibody capture, vector-mediated scFv expression, mouse T-cell tumor transplantation assay","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 — specific intracellular antibody with in vivo functional consequence","pmids":["18438427"],"is_preprint":false},{"year":2009,"finding":"miR-223 directly binds the LMO2 3' UTR to reduce LMO2 mRNA and protein levels; enforced miR-223 expression impairs erythroid differentiation, and LMO2 knockdown by siRNA mimics this effect, establishing miR-223 as a negative post-transcriptional regulator of LMO2 during erythropoiesis.","method":"3'UTR reporter assay, siRNA knockdown, forced miRNA expression in CD34+ progenitors, clonogenic assay","journal":"Haematologica","confidence":"High","confidence_rationale":"Tier 2 — direct 3'UTR binding demonstrated with multiple functional validations","pmids":["19278969"],"is_preprint":false},{"year":2009,"finding":"LMO2 expression is controlled by an array of tissue-specific regulatory elements spread over >100 kb; Sfpi1/Pu.1, Fli1, Gata2, Tal1/Scl, and Lmo2 itself bind to and transactivate Lmo2 hematopoietic enhancers, placing Lmo2 within an autoregulatory hematopoietic network.","method":"Comparative genomics, ChIP-chip across 250 kb locus in 11 cell types, transgenic mouse enhancer assays","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — genome-wide ChIP plus multiple transgenic validations","pmids":["19171877"],"is_preprint":false},{"year":2010,"finding":"The crystal structure of LMO2 in complex with the LDB1-LID domain was solved at 2.4 Å; LMO2 is largely unstructured and kept in register by LID binding both LIM domains; conformational flexibility around a conserved hinge is necessary for binding to SCL/TAL1 in vitro and for function in vivo.","method":"X-ray crystallography at 2.4 Å, in vitro binding assays, in vivo functional rescue","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1 — crystal structure plus in vitro and in vivo functional validation","pmids":["21076045"],"is_preprint":false},{"year":2010,"finding":"c-Myb binds to the LMO2 promoter and transactivates LMO2 expression; c-myb silencing in CD34+ cells impairs erythroid differentiation, and LMO2 overexpression partially rescues the erythroid defect, placing c-myb upstream of LMO2 in erythropoiesis.","method":"Chromatin immunoprecipitation, luciferase reporter assay, retroviral overexpression, c-myb siRNA knockdown","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — ChIP plus reporter plus rescue experiments with defined phenotype","pmids":["20686118"],"is_preprint":false},{"year":2010,"finding":"In DLBCL, the LMO2 complex contains LDB1, E2A, HEB, Lyl1, ETO2, and SP1 but not TAL1 or GATA proteins; novel partners ELK1, NFATc1, and LEF1 were identified; LMO2 increases NFATc1 transcriptional activity and decreases LEF1 activity.","method":"Co-immunoprecipitation/MS interactome, reporter assays","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 — MS interactome with reporter functional follow-up, single lab","pmids":["22517897"],"is_preprint":false},{"year":2011,"finding":"The GATA1 N-terminal finger can simultaneously bind both LMO2 and FOG1; LMO2 in turn simultaneously contacts GATA1 and TAL1/E2A at bipartite E-box/WGATAR sites, providing structural evidence for cooccupancy of FOG1 and TAL1/E2A/LMO2/LDB1 at GATA1-dependent genes.","method":"NMR structure, EMSA, pulldown assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — structural data combined with biochemical interaction assays","pmids":["21844373"],"is_preprint":false},{"year":2012,"finding":"KDM3B, a JmjC domain-containing histone H3K9-me1/2 demethylase, activates lmo2 expression through synergistic interaction with the histone acetyltransferase CBP; KDM3B occupies the lmo2 locus and its knockdown reduces LMO2 levels.","method":"ChIP-chip genome-wide, in vitro demethylase assay, co-immunoprecipitation with CBP","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1-2 — genome-wide ChIP plus enzymatic activity assay plus co-IP","pmids":["22615488"],"is_preprint":false},{"year":2013,"finding":"Crystal structure of the (SCL:E47)bHLH:LMO2:LDB1LID complex bound to DNA revealed that LMO2 induces new hydrogen bonds in SCL:E47 upon binding, strengthening heterodimer formation and imposing a rotation on E47 that weakens heterodimer:DNA interaction, shifting DNA-binding to additional partners.","method":"X-ray crystallography of multiprotein-DNA complex, biochemical binding analyses","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 1 — crystal structure of complete multiprotein complex bound to DNA with biochemical validation","pmids":["23831025"],"is_preprint":false},{"year":2013,"finding":"Lmo2 must recruit Lyl1 (but not Scl/Tal1) to DNA to drive T-cell leukemia; Lyl1 deletion abolishes all oncogenic functions of Lmo2 including upregulation of stem cell-like gene signature, aberrant thymocyte self-renewal, and T-cell leukemia development.","method":"Conditional knockout of Scl or Lyl1 in Lmo2-transgenic mice, transplantation assay, gene expression profiling","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis with conditional KO, multiple oncogenic phenotypes assessed","pmids":["23926305"],"is_preprint":false},{"year":2013,"finding":"GATA2 and Lmo2 directly regulate neuropilin-2 (NRP2) expression in endothelial cells; silencing either factor reduces NRP2 at protein, mRNA and promoter levels, and NRP2 overexpression partially rescues impaired angiogenic sprouting caused by GATA2/Lmo2 knockdown.","method":"siRNA knockdown, promoter reporter assay, NRP2 rescue overexpression, embryoid body angiogenesis assay","journal":"Angiogenesis","confidence":"High","confidence_rationale":"Tier 2 — loss-of-function with specific molecular target identified and rescue validation","pmids":["23892628"],"is_preprint":false},{"year":2014,"finding":"HHEX is a direct transcriptional target of LMO2; LMO2 occupies the HHEX promoter, and conditional inactivation of Hhex in CD2-Lmo2 transgenic mice markedly attenuates T-ALL development, establishing HHEX as a crucial mediator of Lmo2's oncogenic function.","method":"ChIP, conditional knockout of Hhex in Lmo2-transgenic mice, T-ALL development monitoring","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 — direct ChIP of LMO2 at HHEX promoter combined with conditional KO epistasis","pmids":["24465765"],"is_preprint":false},{"year":2014,"finding":"A conformational difference in the LMO2 LIM domain positioning (bending at a central helical region) was revealed by crystal structure of LMO2 with an inhibitory single-domain antibody, supporting a model in which newly synthesized LMO2 is intrinsically disordered and binds a partner protein to nucleate further complex assembly.","method":"X-ray crystallography of LMO2:VH single-domain antibody complex","journal":"Scientific reports","confidence":"High","confidence_rationale":"Tier 1 — crystal structure revealing conformational mechanism","pmids":["24407558"],"is_preprint":false},{"year":2016,"finding":"LMO2 is recruited to DNA replication origins through interaction with POLD1 (DNA polymerase delta), PRIM1 (DNA primase), and MCM6; tethering LMO2 to synthetic DNA sequences converts them into replication origins; lowering LMO2 in erythroid progenitors delays G1-S progression, while ectopic expression in thymocytes drives DNA replication and cell cycle entry.","method":"Co-immunoprecipitation with replication enzymes, synthetic origin tethering assay, BrdU incorporation, ChIP at replication origins","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1-2 — in vitro reconstitution with replication enzymes, tethering assay, multiple orthogonal methods","pmids":["26764384"],"is_preprint":false},{"year":2017,"finding":"In basal-type breast cancer cells, LMO2 localizes predominantly to the cytoplasm where it interacts with cofilin1 to regulate actin cytoskeleton dynamics, promoting tumor cell migration and invasion.","method":"Subcellular fractionation, co-immunoprecipitation with cofilin1, migration/invasion assays, SCID mouse metastasis model","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 3 — single Co-IP with functional invasion assay, single lab","pmids":["27880729"],"is_preprint":false},{"year":2017,"finding":"Lmo2 directly regulates Sphk1 gene expression in endothelial cells by binding to the Sphk1 promoter (shown by ChIP-PCR); Lmo2 knockdown reduces Sphk1 expression and impairs endothelial cell migration and intersegmental vessel formation; Sphk1 mRNA rescues the Lmo2 KD phenotype.","method":"ChIP-PCR, morpholino knockdown in zebrafish, scratch assay, aortic ring assay, mRNA rescue","journal":"Arteriosclerosis, thrombosis, and vascular biology","confidence":"High","confidence_rationale":"Tier 2 — ChIP at specific promoter plus in vivo loss-of-function with rescue","pmids":["28775072"],"is_preprint":false},{"year":2017,"finding":"Recurrent intronic mutations in LMO2 in T-ALL create de novo MYB, ETS1, or RUNX1 binding sites that activate a neomorphic promoter, causing monoallelic LMO2 overexpression; CRISPR/Cas9 disruption of the mutant allele markedly downregulates LMO2 expression.","method":"5'-capped RNA transcript mapping, CRISPR/Cas9 allele-specific disruption, transcription factor binding site analysis","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — CRISPR causality experiment with molecular mechanism established","pmids":["28270453"],"is_preprint":false},{"year":2017,"finding":"LMO2 is required for TAL1 DNA-binding activity at hematopoietic regulatory elements; in Lmo2-/- cells, target site recognition of TAL1 is impaired genome-wide, and LMO2 positions the TAL1/LMO2/LDB1 complex at regulatory elements important for the haematopoietic developmental program.","method":"Lmo2-/- ES cell differentiation, genome-wide ChIP-seq for TAL1 and LMO2, comparison with Tal1-/- cells","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 2 — genome-wide ChIP-seq in matched KO cells, mechanistic interpretation supported by multiple datasets","pmids":["28973433"],"is_preprint":false},{"year":2019,"finding":"LMO2 inhibits BRCA1 recruitment to DNA double-strand breaks by interacting with 53BP1 during repair, rendering LMO2-positive DLBCL and T-ALL cells deficient in homologous recombination and sensitive to PARP inhibitors.","method":"Co-immunoprecipitation of LMO2 with 53BP1, BRCA1 recruitment assay at DSB sites, HR functional assay, PARP inhibitor sensitivity","journal":"Cancer cell","confidence":"High","confidence_rationale":"Tier 2 — Co-IP with mechanistic HR assay and pharmacological validation","pmids":["31447348"],"is_preprint":false},{"year":2019,"finding":"LMO2 is deacetylated on lysine 74 and 78 by the NAMPT/SIRT2 pathway; deacetylation enables LMO2 to interact with LDB1 and activate the TAL1 complex; NAMPT or SIRT2 inhibition suppresses T-ALL cell growth by diminishing LMO2 deacetylation.","method":"Mass spectrometry of LMO2 acetylation sites, SIRT2 deacetylase assay, Co-IP of deacetylated LMO2 with LDB1, NAMPT/SIRT2 inhibitor treatment, zebrafish blood formation assay","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1-2 — PTM identified by MS, enzymatic validation, interaction consequence, in vivo functional data","pmids":["31366618"],"is_preprint":false},{"year":2021,"finding":"Lmo2 directly binds the prdm16 promoter in endothelial cells (shown by ChIP-PCR) and regulates prdm16 transcription; lmo2 loss-of-function in zebrafish reduces prdm16 expression and impairs angiogenesis, establishing an Lmo2-Prdm16 axis in angiogenesis.","method":"ChIP-PCR, lmo2 loss-of-function zebrafish, RNA-seq comparison of endothelial cell populations","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP at specific promoter with in vivo loss-of-function, single lab","pmids":["34330825"],"is_preprint":false},{"year":2005,"finding":"Human Bex2 specifically interacts with LMO2 (shown by GST pull-down and co-immunoprecipitation) and forms part of a DNA-binding complex with LMO2, enhancing LMO2 transcriptional activity; LMO2 also interacts with neuronal bHLH protein NSCL2 and upregulates NSCL2-dependent transcription.","method":"GST pull-down, co-immunoprecipitation, EMSA, mammalian two-hybrid, reporter assay","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 2 — multiple interaction methods with functional reporter data, single lab","pmids":["16314316"],"is_preprint":false},{"year":1995,"finding":"The N-terminal portions of RBTN1 and RBTN2 (LMO2) support transcriptional transactivation in transfection assays; the NH2-terminal 27 amino acids of RBTN2 are sufficient for transactivation in yeast, and RBTN2 forms homodimers.","method":"Transfection reporter assays, yeast two-hybrid and transactivation assay","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 — functional domain mapping with reporter assays","pmids":["7731680"],"is_preprint":false},{"year":2012,"finding":"LMO2 directly assembles TAL1-E47/LYL1 dimers with GATA2 at the ANG-2 promoter in endothelial cells; ChIP demonstrated occupancy of TAL1, LYL1, LMO2, and GATA2 at an E-box/GATA composite element; knockdown of any factor reduces ANG-2 expression.","method":"ChIP, siRNA knockdown, promoter reporter assay, co-immunoprecipitation","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 — direct ChIP of LMO2 and partners at endogenous promoter with loss-of-function validation","pmids":["22792348"],"is_preprint":false}],"current_model":"LMO2 is a LIM-only scaffolding protein that functions as a conformationally flexible bridge within multiprotein transcriptional complexes—including TAL1/SCL, LDB1, GATA1/2, and E-proteins—to regulate hematopoietic and endothelial gene expression programs; its activity is modulated by SIRT2-mediated deacetylation (enabling LDB1 interaction), proteasomal stabilization via SCL binding, and miR-223-mediated translational repression, while in addition to its transcriptional role LMO2 directly promotes DNA replication by interacting with POLD1, PRIM1, and MCM6 at origins, and in DLBCL it inhibits homologous recombination by sequestering 53BP1 away from BRCA1 at DSBs."},"narrative":{"teleology":[{"year":1994,"claim":"Loss-of-function established LMO2 as indispensable for primitive erythropoiesis, answering whether this T-ALL translocation target had a normal developmental role.","evidence":"Homologous recombination knockout in mice causing embryonic lethal failure of yolk sac erythropoiesis","pmids":["8033210"],"confidence":"High","gaps":["Mechanism of action (transcription factor? cofactor?) unknown","Role in definitive hematopoiesis not yet tested","Downstream targets unidentified"]},{"year":1994,"claim":"Identification of the LMO2–TAL1 physical complex in erythroid cells provided the first evidence that two T-ALL oncogenes cooperate through direct protein interaction in normal hematopoiesis.","evidence":"Reciprocal co-immunoprecipitation in erythroid cell lines","pmids":["8078932"],"confidence":"High","gaps":["Stoichiometry and additional complex members unknown","DNA binding of the complex not demonstrated"]},{"year":1995,"claim":"Discovery that LMO2 bridges TAL1 to GATA1/GATA2 and E47 defined the multiprotein architecture through which LMO2 links hematopoietic transcription factors on DNA.","evidence":"In vitro pull-down, co-IP, and mammalian two-hybrid","pmids":["7568177","9209374"],"confidence":"High","gaps":["3D structure of the complex unknown","Direct DNA target genes not identified"]},{"year":1996,"claim":"Demonstration that LMO2 and TAL1 synergize to accelerate T-cell leukemia in vivo established the oncogenic mechanism as a physical protein dimer in thymocytes.","evidence":"Double-transgenic mice with protein dimerization detection and tumor latency comparison","pmids":["8605871"],"confidence":"High","gaps":["Identity of the critical partner in T-ALL (TAL1 vs. LYL1) not resolved","Downstream oncogenic transcriptional targets unknown"]},{"year":1997,"claim":"Identification of LDB1 as a stable partner of LMO2 added the fourth core subunit to the hematopoietic complex and showed that this complex maintains erythroid precursors in an immature state.","evidence":"Co-IP in murine erythroleukemia cells, EMSA, and forced expression in proerythroblasts","pmids":["9391090"],"confidence":"High","gaps":["Structural basis of LMO2–LDB1 interaction unknown","How complex stoichiometry is regulated unclear"]},{"year":1998,"claim":"Chimeric mouse experiments proved LMO2 is required for all adult hematopoietic lineages, not just primitive erythropoiesis, and that this requirement could be rescued by transgene re-expression.","evidence":"Lmo2-null ES cell chimeras with retroviral rescue","pmids":["9520463"],"confidence":"High","gaps":["Whether LMO2 acts at the level of HSC self-renewal or differentiation unclear","Cell-type-specific complex composition not explored"]},{"year":2000,"claim":"Establishing that LMO2 is required for angiogenic remodeling but not de novo vasculogenesis extended its function beyond blood to endothelium.","evidence":"Lmo2-null ES cell chimeras with vascular phenotyping","pmids":["10618416"],"confidence":"High","gaps":["Endothelial target genes of LMO2 unknown","Whether the same TAL1-containing complex operates in endothelium unclear"]},{"year":2003,"claim":"NMR structure of LMO2:LDB1-LID provided the first atomic-resolution view of how LDB1 binds as an extended strand to the LIM1 domain, revealing the structural basis of the core scaffolding interaction.","evidence":"NMR structure determination","pmids":["12727888"],"confidence":"High","gaps":["Full pentameric complex structure on DNA not available","Conformational dynamics between LIM domains uncharacterized"]},{"year":2010,"claim":"The crystal structure of LMO2:LDB1 revealed that LMO2 is largely intrinsically disordered and requires LDB1 to adopt a defined conformation, with a flexible hinge between LIM domains critical for TAL1 binding and in vivo function.","evidence":"X-ray crystallography at 2.4 Å with mutant rescue in zebrafish","pmids":["21076045"],"confidence":"High","gaps":["Hinge dynamics in solution not measured","How disorder-to-order transition is regulated in the cell unknown"]},{"year":2011,"claim":"Structural demonstration that GATA1 simultaneously contacts LMO2 and FOG1 resolved how FOG1-dependent and TAL1/LMO2-dependent gene regulation can co-occur at the same GATA1-bound sites.","evidence":"NMR structure, EMSA, and pulldown assays","pmids":["21844373"],"confidence":"High","gaps":["Genome-wide co-occupancy of FOG1 and LMO2 complex not mapped","Whether this dual binding mode operates at all GATA1 targets unclear"]},{"year":2012,"claim":"Identification of an LMO2–TAL1/LYL1–GATA2 complex at the ANG-2 promoter in endothelial cells demonstrated a direct endothelial transcriptional target and showed the hematopoietic-type complex operates in vasculature.","evidence":"ChIP at endogenous ANG-2 promoter with siRNA knockdown of each factor","pmids":["22792348"],"confidence":"High","gaps":["Genome-wide endothelial target repertoire not defined","Complex composition may differ across vascular beds"]},{"year":2013,"claim":"The crystal structure of the full (SCL:E47)bHLH:LMO2:LDB1 complex on DNA revealed that LMO2 allosterically strengthens the SCL:E47 heterodimer while rotating E47 to weaken its DNA grip, explaining how LMO2 shifts DNA-binding specificity.","evidence":"X-ray crystallography of multiprotein–DNA complex with biochemical validation","pmids":["23831025"],"confidence":"High","gaps":["Whether this allosteric mechanism applies to LYL1-containing complexes unknown","In vivo consequences of the rotational shift not directly tested"]},{"year":2013,"claim":"Genetic epistasis showed that LYL1, not SCL/TAL1, is the obligate bHLH partner recruited by LMO2 to drive T-cell leukemia, resolving a longstanding ambiguity about the oncogenic complex composition.","evidence":"Conditional knockout of Scl or Lyl1 in Lmo2-transgenic mice with transplantation and gene expression profiling","pmids":["23926305"],"confidence":"High","gaps":["How LMO2 selects LYL1 over TAL1 in thymocytes not mechanistically explained","Direct LYL1:LMO2 binding affinity not measured"]},{"year":2016,"claim":"Discovery that LMO2 interacts with replication machinery (POLD1, PRIM1, MCM6) and can convert arbitrary DNA into a replication origin revealed an unexpected non-transcriptional function in DNA replication initiation.","evidence":"Co-IP with replication enzymes, synthetic origin tethering assay, BrdU incorporation, ChIP at origins","pmids":["26764384"],"confidence":"High","gaps":["Whether replication function is separable from transcriptional function in vivo unclear","Structural basis of LMO2–replication machinery interaction unknown","Relevance to normal vs. oncogenic replication programs not delineated"]},{"year":2017,"claim":"Genome-wide ChIP-seq in Lmo2-knockout cells proved that LMO2 is required for TAL1 chromatin occupancy at hematopoietic regulatory elements, establishing LMO2 as a positioning factor rather than a passive scaffold.","evidence":"Lmo2−/− ES cell differentiation with genome-wide TAL1 and LMO2 ChIP-seq","pmids":["28973433"],"confidence":"High","gaps":["Mechanism by which LMO2 enables TAL1 DNA binding (chromatin opening vs. direct tethering) not resolved"]},{"year":2019,"claim":"LMO2 was shown to impair homologous recombination by sequestering 53BP1 from BRCA1 at DSBs, providing a non-transcriptional mechanism for its role in DLBCL biology and creating a therapeutic vulnerability to PARP inhibitors.","evidence":"Co-IP of LMO2 with 53BP1, BRCA1 recruitment assay, HR functional assay, PARP inhibitor sensitivity in DLBCL and T-ALL cells","pmids":["31447348"],"confidence":"High","gaps":["Whether the LMO2–53BP1 interaction is direct or bridged unknown","Structural details of the interaction not available","Clinical efficacy of PARP inhibitors in LMO2-expressing tumors not established"]},{"year":2019,"claim":"Identification of SIRT2-mediated deacetylation of LMO2 at K74/K78 as a prerequisite for LDB1 binding revealed the first post-translational regulatory switch controlling LMO2 complex assembly.","evidence":"Mass spectrometry acetylation mapping, SIRT2 deacetylase assay, Co-IP of deacetylated LMO2 with LDB1, NAMPT/SIRT2 inhibitor treatment, zebrafish assay","pmids":["31366618"],"confidence":"High","gaps":["Which acetyltransferase acetylates LMO2 not identified","Whether acetylation state also regulates replication or DNA repair functions unknown"]},{"year":null,"claim":"How LMO2's transcriptional, replication-initiating, and DNA-repair-inhibitory functions are coordinated or partitioned across cell types and cell-cycle phases remains unresolved.","evidence":"","pmids":[],"confidence":"Low","gaps":["No integrative study has tested all three functions in the same cell system","Structural basis for LMO2 interaction with replication machinery and 53BP1 lacking","Whether LMO2 post-translational modifications differentially regulate each function is untested"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[2,4,10,18,23]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[2,17,32,37,38]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[1,6,18,32]}],"pathway":[{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[0,5,7,8]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[2,17,32,38]},{"term_id":"R-HSA-69306","term_label":"DNA Replication","supporting_discovery_ids":[28]},{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[33]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[3,24,31,33]}],"complexes":["TAL1/SCL–E47–LMO2–LDB1 complex","LYL1–E2A–LMO2–LDB1 complex","GATA1/2–LMO2–TAL1–E47–LDB1 complex"],"partners":["TAL1","LDB1","GATA1","GATA2","LYL1","53BP1","POLD1","PRIM1"],"other_free_text":[]},"mechanistic_narrative":"LMO2 is a LIM-only transcriptional scaffolding protein essential for definitive hematopoiesis, erythropoiesis, and angiogenic vascular remodeling. It functions as an intrinsically disordered bridge that is stabilized upon binding LDB1 via its LIM domains; this interaction is regulated by SIRT2-mediated deacetylation of Lys74/78 and by SCL/TAL1 binding, which prevents proteasomal degradation [PMID:21076045, PMID:31366618, PMID:17878155]. LMO2 nucleates distinct multiprotein DNA-binding complexes—containing TAL1 or LYL1 with E-proteins, GATA factors, and LDB1—at E-box/GATA composite elements to activate hematopoietic (e.g., HHEX) and endothelial (e.g., ANG-2, NRP2, SPHK1) gene programs, and is required genome-wide for TAL1 chromatin occupancy [PMID:28973433, PMID:22792348, PMID:24465765]. Beyond transcription, LMO2 directly promotes DNA replication by interacting with POLD1, PRIM1, and MCM6 at origins [PMID:26764384], and in DLBCL it impairs homologous recombination by sequestering 53BP1 from BRCA1 at double-strand breaks, conferring PARP-inhibitor sensitivity [PMID:31447348]."},"prefetch_data":{"uniprot":{"accession":"P25791","full_name":"Rhombotin-2","aliases":["Cysteine-rich protein TTG-2","LIM domain only protein 2","LMO-2","T-cell translocation protein 2"],"length_aa":158,"mass_kda":18.4,"function":"Acts with TAL1/SCL to regulate red blood cell development. Also acts with LDB1 to maintain erythroid precursors in an immature state","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/P25791/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/LMO2","classification":"Not Classified","n_dependent_lines":27,"n_total_lines":1208,"dependency_fraction":0.022350993377483443},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/LMO2","total_profiled":1310},"omim":[{"mim_id":"619798","title":"E74-LIKE ETS TRANSCRIPTION FACTOR 2; ELF2","url":"https://www.omim.org/entry/619798"},{"mim_id":"616792","title":"NEUROBLASTOMA, SUSCEPTIBILITY TO, 7; NBLST7","url":"https://www.omim.org/entry/616792"},{"mim_id":"610931","title":"ZINC FINGER GENE IN AUTOIMMUNE THYROID DISEASE 1; ZFAT1","url":"https://www.omim.org/entry/610931"},{"mim_id":"609373","title":"LYSINE DEMETHYLASE 3B; KDM3B","url":"https://www.omim.org/entry/609373"},{"mim_id":"609358","title":"ETS VARIANT TRANSCRIPTION FACTOR 2; ETV2","url":"https://www.omim.org/entry/609358"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoplasm","reliability":"Approved"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in many","driving_tissues":[],"url":"https://www.proteinatlas.org/search/LMO2"},"hgnc":{"alias_symbol":["TTG2","RHOM2","RBTN2"],"prev_symbol":["RBTNL1"]},"alphafold":{"accession":"P25791","domains":[{"cath_id":"2.10.110.10","chopping":"1-86","consensus_level":"high","plddt":87.1395,"start":1,"end":86},{"cath_id":"2.10.110.10","chopping":"91-154","consensus_level":"medium","plddt":95.8897,"start":91,"end":154}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P25791","model_url":"https://alphafold.ebi.ac.uk/files/AF-P25791-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P25791-F1-predicted_aligned_error_v6.png","plddt_mean":90.44},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=LMO2","jax_strain_url":"https://www.jax.org/strain/search?query=LMO2"},"sequence":{"accession":"P25791","fasta_url":"https://rest.uniprot.org/uniprotkb/P25791.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P25791/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P25791"}},"corpus_meta":[{"pmid":"14564000","id":"PMC_14564000","title":"LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1.","date":"2003","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/14564000","citation_count":2778,"is_preprint":false},{"pmid":"8033210","id":"PMC_8033210","title":"The oncogenic cysteine-rich LIM domain protein rbtn2 is essential for erythroid development.","date":"1994","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/8033210","citation_count":540,"is_preprint":false},{"pmid":"1923511","id":"PMC_1923511","title":"TTG-2, a new gene encoding a cysteine-rich protein with the LIM motif, is overexpressed in acute T-cell leukaemia with the t(11;14)(p13;q11).","date":"1991","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/1923511","citation_count":257,"is_preprint":false},{"pmid":"9520463","id":"PMC_9520463","title":"The T cell leukemia LIM protein Lmo2 is necessary for adult mouse hematopoiesis.","date":"1998","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9520463","citation_count":254,"is_preprint":false},{"pmid":"8078932","id":"PMC_8078932","title":"The LIM protein RBTN2 and the basic helix-loop-helix protein TAL1 are present in a complex in erythroid cells.","date":"1994","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/8078932","citation_count":205,"is_preprint":false},{"pmid":"8605871","id":"PMC_8605871","title":"Protein dimerization between Lmo2 (Rbtn2) and Tal1 alters thymocyte development and potentiates T cell tumorigenesis in transgenic mice.","date":"1996","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/8605871","citation_count":178,"is_preprint":false},{"pmid":"7568177","id":"PMC_7568177","title":"Association of erythroid transcription factors: complexes involving the LIM protein RBTN2 and the zinc-finger protein GATA1.","date":"1995","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/7568177","citation_count":177,"is_preprint":false},{"pmid":"10618416","id":"PMC_10618416","title":"The oncogenic LIM-only transcription factor Lmo2 regulates angiogenesis but not vasculogenesis in mice.","date":"2000","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/10618416","citation_count":147,"is_preprint":false},{"pmid":"9391090","id":"PMC_9391090","title":"The LIM-domain binding protein Ldb1 and its partner LMO2 act as negative regulators of erythroid differentiation.","date":"1997","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9391090","citation_count":138,"is_preprint":false},{"pmid":"17038524","id":"PMC_17038524","title":"The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B-cell lymphomas.","date":"2006","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/17038524","citation_count":134,"is_preprint":false},{"pmid":"16873670","id":"PMC_16873670","title":"The cryptic chromosomal deletion del(11)(p12p13) as a new activation mechanism of LMO2 in pediatric T-cell acute lymphoblastic leukemia.","date":"2006","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/16873670","citation_count":130,"is_preprint":false},{"pmid":"27046632","id":"PMC_27046632","title":"TTG2 controls the developmental regulation of seed coat tannins in Arabidopsis by regulating vacuolar transport steps in the proanthocyanidin pathway.","date":"2016","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/27046632","citation_count":122,"is_preprint":false},{"pmid":"19278969","id":"PMC_19278969","title":"MicroRNA 223-dependent expression of LMO2 regulates normal erythropoiesis.","date":"2009","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/19278969","citation_count":120,"is_preprint":false},{"pmid":"17090656","id":"PMC_17090656","title":"The transcription factors Scl and Lmo2 act together during development of the hemangioblast in zebrafish.","date":"2006","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/17090656","citation_count":118,"is_preprint":false},{"pmid":"1461647","id":"PMC_1461647","title":"T-cell acute lymphoblastic lymphoma induced in transgenic mice by the RBTN1 and RBTN2 LIM-domain genes.","date":"1992","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/1461647","citation_count":112,"is_preprint":false},{"pmid":"19071961","id":"PMC_19071961","title":"The maternally expressed WRKY transcription factor TTG2 controls lethality in interploidy crosses of Arabidopsis.","date":"2008","source":"PLoS biology","url":"https://pubmed.ncbi.nlm.nih.gov/19071961","citation_count":106,"is_preprint":false},{"pmid":"28105033","id":"PMC_28105033","title":"A Grapevine TTG2-Like WRKY Transcription Factor Is Involved in Regulating Vacuolar Transport and Flavonoid Biosynthesis.","date":"2017","source":"Frontiers in plant science","url":"https://pubmed.ncbi.nlm.nih.gov/28105033","citation_count":96,"is_preprint":false},{"pmid":"22615488","id":"PMC_22615488","title":"KDM3B is the H3K9 demethylase involved in transcriptional activation of lmo2 in leukemia.","date":"2012","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/22615488","citation_count":94,"is_preprint":false},{"pmid":"16260184","id":"PMC_16260184","title":"The role of LMO2 in development and in T cell leukemia after chromosomal translocation or retroviral insertion.","date":"2005","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/16260184","citation_count":94,"is_preprint":false},{"pmid":"9707419","id":"PMC_9707419","title":"The oncogenic T cell LIM-protein Lmo2 forms part of a DNA-binding complex specifically in immature T cells.","date":"1998","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/9707419","citation_count":94,"is_preprint":false},{"pmid":"20686118","id":"PMC_20686118","title":"c-myb supports erythropoiesis through the transactivation of KLF1 and LMO2 expression.","date":"2010","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/20686118","citation_count":92,"is_preprint":false},{"pmid":"20457870","id":"PMC_20457870","title":"A self-inactivating lentiviral vector for SCID-X1 gene therapy that does not activate LMO2 expression in human T cells.","date":"2010","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/20457870","citation_count":90,"is_preprint":false},{"pmid":"10631184","id":"PMC_10631184","title":"Lmo2 and GATA-3 associated expression in intraembryonic hemogenic sites.","date":"2000","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/10631184","citation_count":86,"is_preprint":false},{"pmid":"7970726","id":"PMC_7970726","title":"T cell tumours of disparate phenotype in mice transgenic for Rbtn-2.","date":"1994","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/7970726","citation_count":86,"is_preprint":false},{"pmid":"21670468","id":"PMC_21670468","title":"Notch1 inhibition targets the leukemia-initiating cells in a Tal1/Lmo2 mouse model of T-ALL.","date":"2011","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/21670468","citation_count":84,"is_preprint":false},{"pmid":"15893977","id":"PMC_15893977","title":"Regulation of the lmo2 promoter during hematopoietic and vascular development in zebrafish.","date":"2005","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/15893977","citation_count":82,"is_preprint":false},{"pmid":"7545805","id":"PMC_7545805","title":"The oncogenic LIM protein Rbtn2 causes thymic developmental aberrations that precede malignancy in transgenic mice.","date":"1995","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/7545805","citation_count":78,"is_preprint":false},{"pmid":"11493549","id":"PMC_11493549","title":"Primitive erythropoiesis in the Xenopus embryo: the synergistic role of LMO-2, SCL and GATA-binding proteins.","date":"2001","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/11493549","citation_count":73,"is_preprint":false},{"pmid":"28270453","id":"PMC_28270453","title":"Activation of the LMO2 oncogene through a somatically acquired neomorphic promoter in T-cell acute lymphoblastic leukemia.","date":"2017","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/28270453","citation_count":67,"is_preprint":false},{"pmid":"19171877","id":"PMC_19171877","title":"Expression of the leukemia oncogene Lmo2 is controlled by an array of tissue-specific elements dispersed over 100 kb and bound by Tal1/Lmo2, Ets, and Gata factors.","date":"2009","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/19171877","citation_count":66,"is_preprint":false},{"pmid":"25304203","id":"PMC_25304203","title":"Arabidopsis TTG2 regulates TRY expression through enhancement of activator complex-triggered activation.","date":"2014","source":"The Plant cell","url":"https://pubmed.ncbi.nlm.nih.gov/25304203","citation_count":63,"is_preprint":false},{"pmid":"31447348","id":"PMC_31447348","title":"LMO2 Confers Synthetic Lethality to PARP Inhibition in DLBCL.","date":"2019","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/31447348","citation_count":63,"is_preprint":false},{"pmid":"19461887","id":"PMC_19461887","title":"Murine leukemias with retroviral insertions at Lmo2 are predictive of the leukemias induced in SCID-X1 patients following retroviral gene therapy.","date":"2009","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19461887","citation_count":62,"is_preprint":false},{"pmid":"12727888","id":"PMC_12727888","title":"Structural basis for the recognition of ldb1 by the N-terminal LIM domains of LMO2 and LMO4.","date":"2003","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/12727888","citation_count":61,"is_preprint":false},{"pmid":"21076045","id":"PMC_21076045","title":"Structure of the leukemia oncogene LMO2: implications for the assembly of a hematopoietic transcription factor complex.","date":"2010","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/21076045","citation_count":60,"is_preprint":false},{"pmid":"26108219","id":"PMC_26108219","title":"LMO2 at 25 years: a paradigm of chromosomal translocation proteins.","date":"2015","source":"Open biology","url":"https://pubmed.ncbi.nlm.nih.gov/26108219","citation_count":59,"is_preprint":false},{"pmid":"23926305","id":"PMC_23926305","title":"Requirement for Lyl1 in a model of Lmo2-driven early T-cell precursor ALL.","date":"2013","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/23926305","citation_count":58,"is_preprint":false},{"pmid":"23831025","id":"PMC_23831025","title":"Structural basis for LMO2-driven recruitment of the SCL:E47bHLH heterodimer to hematopoietic-specific transcriptional targets.","date":"2013","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/23831025","citation_count":57,"is_preprint":false},{"pmid":"24465765","id":"PMC_24465765","title":"LIM domain only-2 (LMO2) induces T-cell leukemia by two distinct pathways.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24465765","citation_count":51,"is_preprint":false},{"pmid":"15994290","id":"PMC_15994290","title":"Fli1, Elf1, and Ets1 regulate the proximal promoter of the LMO2 gene in endothelial cells.","date":"2005","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/15994290","citation_count":51,"is_preprint":false},{"pmid":"17167821","id":"PMC_17167821","title":"The significance of LMO2 expression in the progression of prostate cancer.","date":"2007","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/17167821","citation_count":48,"is_preprint":false},{"pmid":"10197599","id":"PMC_10197599","title":"The effect of chromosomal translocations in acute leukemias: the LMO2 paradigm in transcription and development.","date":"1999","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/10197599","citation_count":47,"is_preprint":false},{"pmid":"23892628","id":"PMC_23892628","title":"GATA2 and Lmo2 control angiogenesis and lymphangiogenesis via direct transcriptional regulation of neuropilin-2.","date":"2013","source":"Angiogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/23892628","citation_count":46,"is_preprint":false},{"pmid":"23378057","id":"PMC_23378057","title":"Lmo2 induces hematopoietic stem cell-like features in T-cell progenitor cells prior to leukemia.","date":"2013","source":"Stem cells (Dayton, Ohio)","url":"https://pubmed.ncbi.nlm.nih.gov/23378057","citation_count":45,"is_preprint":false},{"pmid":"11857074","id":"PMC_11857074","title":"The LIM-domain protein Lmo2 is a key regulator of tumour angiogenesis: a new anti-angiogenesis drug target.","date":"2002","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/11857074","citation_count":44,"is_preprint":false},{"pmid":"25721045","id":"PMC_25721045","title":"The LIM-only transcription factor LMO2 determines tumorigenic and angiogenic traits in glioma stem cells.","date":"2015","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/25721045","citation_count":41,"is_preprint":false},{"pmid":"21844373","id":"PMC_21844373","title":"Structural basis of simultaneous recruitment of the transcriptional regulators LMO2 and FOG1/ZFPM1 by the transcription factor GATA1.","date":"2011","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/21844373","citation_count":41,"is_preprint":false},{"pmid":"17360939","id":"PMC_17360939","title":"Different chromosomal breakpoints impact the level of LMO2 expression in T-ALL.","date":"2007","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/17360939","citation_count":41,"is_preprint":false},{"pmid":"26071533","id":"PMC_26071533","title":"Expression of Brassica napus TTG2, a regulator of trichome development, increases plant sensitivity to salt stress by suppressing the expression of auxin biosynthesis genes.","date":"2015","source":"Journal of experimental botany","url":"https://pubmed.ncbi.nlm.nih.gov/26071533","citation_count":39,"is_preprint":false},{"pmid":"22517897","id":"PMC_22517897","title":"Identification of LMO2 transcriptome and interactome in diffuse large B-cell lymphoma.","date":"2012","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/22517897","citation_count":38,"is_preprint":false},{"pmid":"18438427","id":"PMC_18438427","title":"An antibody inhibitor of the LMO2-protein complex blocks its normal and tumorigenic functions.","date":"2008","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/18438427","citation_count":38,"is_preprint":false},{"pmid":"7731686","id":"PMC_7731686","title":"The TTG-2/RBTN2 T cell oncogene encodes two alternative transcripts from two promoters: the distal promoter is removed by most 11p13 translocations in acute T cell leukaemia's (T-ALL).","date":"1995","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/7731686","citation_count":37,"is_preprint":false},{"pmid":"22819672","id":"PMC_22819672","title":"Abnormal vasculature interferes with optic fissure closure in lmo2 mutant zebrafish embryos.","date":"2012","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/22819672","citation_count":36,"is_preprint":false},{"pmid":"17878155","id":"PMC_17878155","title":"Protein stability and transcription factor complex assembly determined by the SCL-LMO2 interaction.","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17878155","citation_count":35,"is_preprint":false},{"pmid":"20676125","id":"PMC_20676125","title":"A previously unrecognized promoter of LMO2 forms part of a transcriptional regulatory circuit mediating LMO2 expression in a subset of T-acute lymphoblastic leukaemia patients.","date":"2010","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/20676125","citation_count":35,"is_preprint":false},{"pmid":"16314316","id":"PMC_16314316","title":"Human Bex2 interacts with LMO2 and regulates the transcriptional activity of a novel DNA-binding complex.","date":"2005","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/16314316","citation_count":35,"is_preprint":false},{"pmid":"20697248","id":"PMC_20697248","title":"Immunoarchitectural patterns in follicular lymphoma: efficacy of HGAL and LMO2 in the detection of the interfollicular and diffuse components.","date":"2010","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/20697248","citation_count":35,"is_preprint":false},{"pmid":"19487290","id":"PMC_19487290","title":"Targeting LMO2 with a peptide aptamer establishes a necessary function in overt T-cell neoplasia.","date":"2009","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/19487290","citation_count":35,"is_preprint":false},{"pmid":"20519628","id":"PMC_20519628","title":"Aberrant induction of LMO2 by the E2A-HLF chimeric transcription factor and its implication in leukemogenesis of B-precursor ALL with t(17;19).","date":"2010","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/20519628","citation_count":34,"is_preprint":false},{"pmid":"17942750","id":"PMC_17942750","title":"Fibroblast growth factor controls the timing of Scl, Lmo2, and Runx1 expression during embryonic blood development.","date":"2007","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/17942750","citation_count":34,"is_preprint":false},{"pmid":"29880602","id":"PMC_29880602","title":"Lmo2 expression defines tumor cell identity during T-cell leukemogenesis.","date":"2018","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/29880602","citation_count":34,"is_preprint":false},{"pmid":"21072044","id":"PMC_21072044","title":"The E2A-HLF oncogenic fusion protein acts through Lmo2 and Bcl-2 to immortalize hematopoietic progenitors.","date":"2010","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/21072044","citation_count":33,"is_preprint":false},{"pmid":"22394247","id":"PMC_22394247","title":"Detection of LIM domain only 2 (LMO2) in normal human tissues and haematopoietic and non-haematopoietic tumours using a newly developed rabbit monoclonal antibody.","date":"2012","source":"Histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/22394247","citation_count":33,"is_preprint":false},{"pmid":"20861166","id":"PMC_20861166","title":"The molecular basis of Lmo2-induced T-cell acute lymphoblastic leukemia.","date":"2010","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/20861166","citation_count":32,"is_preprint":false},{"pmid":"20980262","id":"PMC_20980262","title":"Single domain intracellular antibodies from diverse libraries: emphasizing dual functions of LMO2 protein interactions using a single VH domain.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20980262","citation_count":32,"is_preprint":false},{"pmid":"15541480","id":"PMC_15541480","title":"Negative regulatory elements are present in the human LMO2 oncogene and may contribute to its expression in leukemia.","date":"2005","source":"Leukemia research","url":"https://pubmed.ncbi.nlm.nih.gov/15541480","citation_count":32,"is_preprint":false},{"pmid":"27880729","id":"PMC_27880729","title":"LMO2 promotes tumor cell invasion and metastasis in basal-type breast cancer by altering actin cytoskeleton remodeling.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27880729","citation_count":30,"is_preprint":false},{"pmid":"21057528","id":"PMC_21057528","title":"A DNA-binding mutant of TAL1 cooperates with LMO2 to cause T cell leukemia in mice.","date":"2010","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/21057528","citation_count":30,"is_preprint":false},{"pmid":"25203428","id":"PMC_25203428","title":"Diagnostic Utility of the Germinal Center-associated Markers GCET1, HGAL, and LMO2 in Hematolymphoid Neoplasms.","date":"2015","source":"Applied immunohistochemistry & molecular morphology : AIMM","url":"https://pubmed.ncbi.nlm.nih.gov/25203428","citation_count":30,"is_preprint":false},{"pmid":"27779255","id":"PMC_27779255","title":"LMO2 attenuates tumor growth by targeting the Wnt signaling pathway in breast and colorectal cancer.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27779255","citation_count":29,"is_preprint":false},{"pmid":"22058201","id":"PMC_22058201","title":"Characterization of a pediatric T-cell acute lymphoblastic leukemia patient with simultaneous LYL1 and LMO2 rearrangements.","date":"2011","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/22058201","citation_count":29,"is_preprint":false},{"pmid":"16616188","id":"PMC_16616188","title":"Identification of the key LMO2-binding determinants on Ldb1.","date":"2006","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/16616188","citation_count":29,"is_preprint":false},{"pmid":"19141387","id":"PMC_19141387","title":"The transcription factor LMO2 is a robust marker of vascular endothelium and vascular neoplasms and selected other entities.","date":"2009","source":"American journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/19141387","citation_count":28,"is_preprint":false},{"pmid":"24571259","id":"PMC_24571259","title":"LMO2 and BCL6 are associated with improved survival in primary central nervous system lymphoma.","date":"2014","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/24571259","citation_count":28,"is_preprint":false},{"pmid":"26764384","id":"PMC_26764384","title":"The LMO2 oncogene regulates DNA replication in hematopoietic cells.","date":"2016","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/26764384","citation_count":27,"is_preprint":false},{"pmid":"18627109","id":"PMC_18627109","title":"Functional characterization of Lmo2-Cre transgenic zebrafish.","date":"2008","source":"Developmental dynamics : an official publication of the American Association of Anatomists","url":"https://pubmed.ncbi.nlm.nih.gov/18627109","citation_count":26,"is_preprint":false},{"pmid":"21427293","id":"PMC_21427293","title":"Functional interactions between Lmo2, the Arf tumor suppressor, and Notch1 in murine T-cell malignancies.","date":"2011","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/21427293","citation_count":25,"is_preprint":false},{"pmid":"12609830","id":"PMC_12609830","title":"A PAR domain transcription factor is involved in the expression from a hematopoietic-specific promoter for the human LMO2 gene.","date":"2003","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/12609830","citation_count":25,"is_preprint":false},{"pmid":"30679322","id":"PMC_30679322","title":"ZEB2 and LMO2 drive immature T-cell lymphoblastic leukemia via distinct oncogenic mechanisms.","date":"2019","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/30679322","citation_count":24,"is_preprint":false},{"pmid":"28288039","id":"PMC_28288039","title":"LMO2-negative Expression Predicts the Presence of MYC Translocations in Aggressive B-Cell Lymphomas.","date":"2017","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/28288039","citation_count":24,"is_preprint":false},{"pmid":"17910069","id":"PMC_17910069","title":"Assembly of the oncogenic DNA-binding complex LMO2-Ldb1-TAL1-E12.","date":"2008","source":"Proteins","url":"https://pubmed.ncbi.nlm.nih.gov/17910069","citation_count":24,"is_preprint":false},{"pmid":"9209374","id":"PMC_9209374","title":"LIM-only protein Lmo2 forms a protein complex with erythroid transcription factor GATA-1.","date":"1997","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/9209374","citation_count":23,"is_preprint":false},{"pmid":"28775072","id":"PMC_28775072","title":"Lmo2 (LIM-Domain-Only 2) Modulates Sphk1 (Sphingosine Kinase) and Promotes Endothelial Cell Migration.","date":"2017","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/28775072","citation_count":23,"is_preprint":false},{"pmid":"26796495","id":"PMC_26796495","title":"LMO2 Is a Specific Marker of T-Lymphoblastic Leukemia/Lymphoma.","date":"2016","source":"American journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26796495","citation_count":23,"is_preprint":false},{"pmid":"22792348","id":"PMC_22792348","title":"Angiopoietin-2 is a direct transcriptional target of TAL1, LYL1 and LMO2 in endothelial cells.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22792348","citation_count":22,"is_preprint":false},{"pmid":"16011889","id":"PMC_16011889","title":"SCL, GATA-2 and Lmo2 expression in neurogenesis.","date":"2005","source":"International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/16011889","citation_count":21,"is_preprint":false},{"pmid":"7731680","id":"PMC_7731680","title":"Functional diversity of LIM proteins: amino-terminal activation domains in the oncogenic proteins RBTN1 and RBTN2.","date":"1995","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/7731680","citation_count":20,"is_preprint":false},{"pmid":"31366618","id":"PMC_31366618","title":"LMO2 activation by deacetylation is indispensable for hematopoiesis and T-ALL leukemogenesis.","date":"2019","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/31366618","citation_count":20,"is_preprint":false},{"pmid":"28973433","id":"PMC_28973433","title":"LMO2 is required for TAL1 DNA binding activity and initiation of definitive haematopoiesis at the haemangioblast stage.","date":"2017","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/28973433","citation_count":20,"is_preprint":false},{"pmid":"21502424","id":"PMC_21502424","title":"The efficacy of HGAL and LMO2 in the separation of lymphomas derived from small B cells in nodal and extranodal sites, including the bone marrow.","date":"2011","source":"American journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/21502424","citation_count":20,"is_preprint":false},{"pmid":"25283843","id":"PMC_25283843","title":"Hhex regulates Kit to promote radioresistance of self-renewing thymocytes in Lmo2-transgenic mice.","date":"2014","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/25283843","citation_count":19,"is_preprint":false},{"pmid":"22797922","id":"PMC_22797922","title":"Tobacco TTG2 suppresses resistance to pathogens by sequestering NPR1 from the nucleus.","date":"2012","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/22797922","citation_count":19,"is_preprint":false},{"pmid":"15911088","id":"PMC_15911088","title":"Transcriptional control of fetal liver hematopoiesis: dominant negative effect of the overexpression of the LIM domain mutants of LMO2.","date":"2005","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/15911088","citation_count":19,"is_preprint":false},{"pmid":"33156841","id":"PMC_33156841","title":"TOP1α, UPF1, and TTG2 regulate seed size in a parental dosage-dependent manner.","date":"2020","source":"PLoS biology","url":"https://pubmed.ncbi.nlm.nih.gov/33156841","citation_count":18,"is_preprint":false},{"pmid":"24252253","id":"PMC_24252253","title":"TTG2-regulated development is related to expression of putative AUXIN RESPONSE FACTOR genes in tobacco.","date":"2013","source":"BMC genomics","url":"https://pubmed.ncbi.nlm.nih.gov/24252253","citation_count":18,"is_preprint":false},{"pmid":"33503448","id":"PMC_33503448","title":"LMO2 upregulation due to AR deactivation in cancer-associated fibroblasts induces non-cell-autonomous growth of prostate cancer after androgen deprivation.","date":"2021","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/33503448","citation_count":18,"is_preprint":false},{"pmid":"27255279","id":"PMC_27255279","title":"Tobacco TTG2 regulates vegetative growth and seed production via the predominant role of ARF8 in cooperation with ARF17 and ARF19.","date":"2016","source":"BMC plant biology","url":"https://pubmed.ncbi.nlm.nih.gov/27255279","citation_count":17,"is_preprint":false},{"pmid":"34330825","id":"PMC_34330825","title":"Fli1+ cells transcriptional analysis reveals an Lmo2-Prdm16 axis in angiogenesis.","date":"2021","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/34330825","citation_count":17,"is_preprint":false},{"pmid":"36044573","id":"PMC_36044573","title":"Endothelial versus pronephron fate decision is modulated by the transcription factors Cloche/Npas4l, Tal1, and Lmo2.","date":"2022","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/36044573","citation_count":17,"is_preprint":false},{"pmid":"24407558","id":"PMC_24407558","title":"Conformational flexibility of the oncogenic protein LMO2 primes the formation of the multi-protein transcription complex.","date":"2014","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/24407558","citation_count":16,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":46991,"output_tokens":8502,"usd":0.134251},"stage2":{"model":"claude-opus-4-6","input_tokens":12345,"output_tokens":3838,"usd":0.236512},"total_usd":0.370763,"stage1_batch_id":"msgbatch_01Mgbec4vM6c9vXht7JVJzss","stage2_batch_id":"msgbatch_01JkuuH5RB2BdJNsgnhjbC6s","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1994,\n      \"finding\": \"LMO2 (RBTN2) is a nuclear protein essential for yolk sac erythropoiesis; homologous recombination knockout in mice causes failure of erythroid development and embryonic lethality around E10.5, establishing its pivotal role in lineage specification.\",\n      \"method\": \"Homologous recombination knockout in mice, in vitro differentiation of yolk sac tissue, ES cell targeting\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with defined cellular phenotype, replicated across multiple experimental approaches in one study\",\n      \"pmids\": [\"8033210\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"LMO2 (RBTN2) forms a complex with TAL1 in the nucleus of erythroid cells; RBTN2 is not phosphorylated while TAL1 is a phosphoprotein; both proteins are coexpressed in erythroid cells and are crucial for erythropoiesis.\",\n      \"method\": \"Co-immunoprecipitation with anti-RBTN2 and anti-TAL1 antisera in erythroid cells\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP in native erythroid cells, replicated by multiple labs\",\n      \"pmids\": [\"8078932\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"LMO2 (RBTN2) directly interacts in vivo and in vitro with GATA1 and GATA2 zinc-finger transcription factors, as well as with TAL1; mammalian two-hybrid analysis demonstrated a complex involving RBTN2, TAL1, GATA1, and E47, linking three proteins crucial for erythropoiesis.\",\n      \"method\": \"In vitro pull-down, co-immunoprecipitation, mammalian two-hybrid analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods (in vitro and in vivo), replicated across labs\",\n      \"pmids\": [\"7568177\", \"9209374\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"LMO2 and TAL1 proteins form dimers in thymocytes of double-transgenic mice; co-expression of Lmo2 and Tal1 in T cells alters thymocyte development (accumulation of immature T cells) and potentiates T-cell tumor formation approximately 3 months earlier than Lmo2 alone, demonstrating synergistic oncogenic interaction.\",\n      \"method\": \"Transgenic mouse co-expression, protein dimerization detection in thymocytes, tumor latency comparison\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct protein interaction shown in vivo with clear functional phenotype, strong genetic epistasis\",\n      \"pmids\": [\"8605871\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"LMO2 and Ldb1 exist in a stable complex in murine erythroleukemia cells; Ldb1, LMO2, and SCL/E12 can assemble as a multiprotein complex on a consensus SCL binding site; forced expression of Ldb1 or LMO2 in erythroid progenitor cells inhibits cellular maturation, indicating LMO2-Ldb1 complex maintains erythroid precursors in an immature state.\",\n      \"method\": \"Co-immunoprecipitation, gel shift/EMSA, forced expression in G1ER proerythroblast cells\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP plus functional overexpression with defined cellular phenotype, multiple methods\",\n      \"pmids\": [\"9391090\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Lmo2 null ES cells do not contribute to any hematopoietic lineage in adult chimeric mice, demonstrating Lmo2 is necessary for all adult hematopoiesis; reintroduction of Lmo2 expression vector rescues this defect, and the mechanism likely involves interaction with Tal1/Scl.\",\n      \"method\": \"Chimeric mouse assay with homozygous Lmo2-/- ES cells, rescue by retroviral re-expression\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic loss-of-function with rescue, clear lineage phenotype\",\n      \"pmids\": [\"9520463\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"In T cells from Lmo2 transgenic mice, Lmo2 forms an oligomeric DNA-binding complex that recognizes a bipartite motif of two E-box sequences ~10 bp apart; this complex is restricted to immature CD4-CD8- thymocytes and is distinct from the complex found in erythroid cells.\",\n      \"method\": \"CASTing (cyclic amplification and selection of targets), band shift/EMSA, immunophenotyping\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct DNA-binding complex isolation with sequence specificity, combined with cellular phenotype\",\n      \"pmids\": [\"9707419\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Lmo2 is expressed in vascular endothelium and is required for angiogenic remodeling of the capillary network into mature vasculature but not for de novo vasculogenesis; Lmo2-null ES cells fail to contribute to endothelial cells of large vessel walls after E10, demonstrating a distinct role in angiogenesis.\",\n      \"method\": \"Chimeric mouse analysis with Lmo2-null ES cells, histological and vascular imaging\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean loss-of-function with defined vascular phenotype, replicated in multiple chimeric mice\",\n      \"pmids\": [\"10618416\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"In Xenopus, LMO-2 acts synergistically with SCL and GATA-1 to specify hematopoietic mesoderm; co-expression of all three factors leads to ventralized embryos with ectopic blood, and their interaction in a transcriptional complex was demonstrated in vitro.\",\n      \"method\": \"Xenopus animal cap assay, whole embryo overexpression, in vitro complex assembly\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis in whole embryo with in vitro complex validation\",\n      \"pmids\": [\"11493549\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Lmo2 is an obligatory regulator of tumor neo-vascularization; Lmo2-null ES cells fail to produce CD31-positive sprouting endothelium in teratocarcinomas in nude mice, while heterozygous cells do, establishing Lmo2 as necessary for tumor angiogenesis.\",\n      \"method\": \"Teratocarcinoma model in nude mice using Lmo2-null and heterozygous ES cells, CD31 immunostaining\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean loss-of-function in vivo with defined angiogenic phenotype\",\n      \"pmids\": [\"11857074\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"The solution structures of LMO2:ldb1 and LMO4:ldb1 complexes were determined by NMR; ldb1-LID binds to the N-terminal LIM domain (LIM1) of LMO2 in an extended conformation, contributing a third strand to a beta-hairpin in LIM1, providing the first molecular definition of LIM-mediated protein-protein interactions.\",\n      \"method\": \"NMR structure determination (PDB: 1M3V and 1J2O)\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — NMR structures with functional validation of binding interface\",\n      \"pmids\": [\"12727888\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"The LMO2 proximal promoter is regulated by ETS transcription factors Elf1, Fli1, and Ets1, which bind to three conserved ETS sites in vivo; this promoter is sufficient for endothelial expression in vivo but requires additional enhancers for hematopoietic expression.\",\n      \"method\": \"Chromatin immunoprecipitation, transient/stable transfection, transgenic mouse analysis\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP in vivo binding plus transgenic validation\",\n      \"pmids\": [\"15994290\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Scl and Lmo2 act together in zebrafish hemangioblast development; scl morphants cannot be rescued by a non-Lmo2-binding form of Scl but can be rescued by non-DNA-binding forms, indicating Scl is tethered to target genes through DNA-binding partners via Lmo2.\",\n      \"method\": \"Zebrafish morpholino knockdown, rescue with mutant Scl constructs, epistasis analysis\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis with domain-specific rescue experiments\",\n      \"pmids\": [\"17090656\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"LMO2 and SCL interact through a conserved interface in the SCL loop and helix 2; this interaction nucleates assembly of SCL complexes on DNA, is required for target gene induction and erythroid/megakaryocytic differentiation, and SCL prevents LMO2 degradation by the proteasome.\",\n      \"method\": \"Co-immunoprecipitation, domain mutagenesis, in vitro binding assays, proteasome inhibitor experiments\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — mutagenesis of binding interface combined with functional and protein stability assays\",\n      \"pmids\": [\"17878155\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"The oncogenic LMO2-Ldb1-TAL1-E12 complex was characterized biophysically; TAL1/E12 bHLH preferentially form heterodimers to which LMO2 binds with high affinity (~10^8 M^-1); the resulting complex forms in the presence or absence of DNA and preferentially binds different E-box sequences.\",\n      \"method\": \"Biophysical characterization (analytical ultracentrifugation, ITC), EMSA\",\n      \"journal\": \"Proteins\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution of multiprotein complex with quantitative binding measurements\",\n      \"pmids\": [\"17910069\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"An anti-LMO2 single-chain Fv antibody specific for the LIM3-LIM4 region of LMO2 inhibits Lmo2-dependent erythropoiesis and prevents Lmo2-dependent leukemia in a mouse transplantation assay, demonstrating that interference with the LMO2 multiprotein complex disrupts both normal and tumorigenic roles.\",\n      \"method\": \"Intracellular antibody capture, vector-mediated scFv expression, mouse T-cell tumor transplantation assay\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — specific intracellular antibody with in vivo functional consequence\",\n      \"pmids\": [\"18438427\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"miR-223 directly binds the LMO2 3' UTR to reduce LMO2 mRNA and protein levels; enforced miR-223 expression impairs erythroid differentiation, and LMO2 knockdown by siRNA mimics this effect, establishing miR-223 as a negative post-transcriptional regulator of LMO2 during erythropoiesis.\",\n      \"method\": \"3'UTR reporter assay, siRNA knockdown, forced miRNA expression in CD34+ progenitors, clonogenic assay\",\n      \"journal\": \"Haematologica\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct 3'UTR binding demonstrated with multiple functional validations\",\n      \"pmids\": [\"19278969\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"LMO2 expression is controlled by an array of tissue-specific regulatory elements spread over >100 kb; Sfpi1/Pu.1, Fli1, Gata2, Tal1/Scl, and Lmo2 itself bind to and transactivate Lmo2 hematopoietic enhancers, placing Lmo2 within an autoregulatory hematopoietic network.\",\n      \"method\": \"Comparative genomics, ChIP-chip across 250 kb locus in 11 cell types, transgenic mouse enhancer assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genome-wide ChIP plus multiple transgenic validations\",\n      \"pmids\": [\"19171877\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"The crystal structure of LMO2 in complex with the LDB1-LID domain was solved at 2.4 Å; LMO2 is largely unstructured and kept in register by LID binding both LIM domains; conformational flexibility around a conserved hinge is necessary for binding to SCL/TAL1 in vitro and for function in vivo.\",\n      \"method\": \"X-ray crystallography at 2.4 Å, in vitro binding assays, in vivo functional rescue\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure plus in vitro and in vivo functional validation\",\n      \"pmids\": [\"21076045\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"c-Myb binds to the LMO2 promoter and transactivates LMO2 expression; c-myb silencing in CD34+ cells impairs erythroid differentiation, and LMO2 overexpression partially rescues the erythroid defect, placing c-myb upstream of LMO2 in erythropoiesis.\",\n      \"method\": \"Chromatin immunoprecipitation, luciferase reporter assay, retroviral overexpression, c-myb siRNA knockdown\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP plus reporter plus rescue experiments with defined phenotype\",\n      \"pmids\": [\"20686118\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"In DLBCL, the LMO2 complex contains LDB1, E2A, HEB, Lyl1, ETO2, and SP1 but not TAL1 or GATA proteins; novel partners ELK1, NFATc1, and LEF1 were identified; LMO2 increases NFATc1 transcriptional activity and decreases LEF1 activity.\",\n      \"method\": \"Co-immunoprecipitation/MS interactome, reporter assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — MS interactome with reporter functional follow-up, single lab\",\n      \"pmids\": [\"22517897\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"The GATA1 N-terminal finger can simultaneously bind both LMO2 and FOG1; LMO2 in turn simultaneously contacts GATA1 and TAL1/E2A at bipartite E-box/WGATAR sites, providing structural evidence for cooccupancy of FOG1 and TAL1/E2A/LMO2/LDB1 at GATA1-dependent genes.\",\n      \"method\": \"NMR structure, EMSA, pulldown assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — structural data combined with biochemical interaction assays\",\n      \"pmids\": [\"21844373\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"KDM3B, a JmjC domain-containing histone H3K9-me1/2 demethylase, activates lmo2 expression through synergistic interaction with the histone acetyltransferase CBP; KDM3B occupies the lmo2 locus and its knockdown reduces LMO2 levels.\",\n      \"method\": \"ChIP-chip genome-wide, in vitro demethylase assay, co-immunoprecipitation with CBP\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — genome-wide ChIP plus enzymatic activity assay plus co-IP\",\n      \"pmids\": [\"22615488\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Crystal structure of the (SCL:E47)bHLH:LMO2:LDB1LID complex bound to DNA revealed that LMO2 induces new hydrogen bonds in SCL:E47 upon binding, strengthening heterodimer formation and imposing a rotation on E47 that weakens heterodimer:DNA interaction, shifting DNA-binding to additional partners.\",\n      \"method\": \"X-ray crystallography of multiprotein-DNA complex, biochemical binding analyses\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure of complete multiprotein complex bound to DNA with biochemical validation\",\n      \"pmids\": [\"23831025\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Lmo2 must recruit Lyl1 (but not Scl/Tal1) to DNA to drive T-cell leukemia; Lyl1 deletion abolishes all oncogenic functions of Lmo2 including upregulation of stem cell-like gene signature, aberrant thymocyte self-renewal, and T-cell leukemia development.\",\n      \"method\": \"Conditional knockout of Scl or Lyl1 in Lmo2-transgenic mice, transplantation assay, gene expression profiling\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis with conditional KO, multiple oncogenic phenotypes assessed\",\n      \"pmids\": [\"23926305\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"GATA2 and Lmo2 directly regulate neuropilin-2 (NRP2) expression in endothelial cells; silencing either factor reduces NRP2 at protein, mRNA and promoter levels, and NRP2 overexpression partially rescues impaired angiogenic sprouting caused by GATA2/Lmo2 knockdown.\",\n      \"method\": \"siRNA knockdown, promoter reporter assay, NRP2 rescue overexpression, embryoid body angiogenesis assay\",\n      \"journal\": \"Angiogenesis\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function with specific molecular target identified and rescue validation\",\n      \"pmids\": [\"23892628\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"HHEX is a direct transcriptional target of LMO2; LMO2 occupies the HHEX promoter, and conditional inactivation of Hhex in CD2-Lmo2 transgenic mice markedly attenuates T-ALL development, establishing HHEX as a crucial mediator of Lmo2's oncogenic function.\",\n      \"method\": \"ChIP, conditional knockout of Hhex in Lmo2-transgenic mice, T-ALL development monitoring\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct ChIP of LMO2 at HHEX promoter combined with conditional KO epistasis\",\n      \"pmids\": [\"24465765\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"A conformational difference in the LMO2 LIM domain positioning (bending at a central helical region) was revealed by crystal structure of LMO2 with an inhibitory single-domain antibody, supporting a model in which newly synthesized LMO2 is intrinsically disordered and binds a partner protein to nucleate further complex assembly.\",\n      \"method\": \"X-ray crystallography of LMO2:VH single-domain antibody complex\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure revealing conformational mechanism\",\n      \"pmids\": [\"24407558\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"LMO2 is recruited to DNA replication origins through interaction with POLD1 (DNA polymerase delta), PRIM1 (DNA primase), and MCM6; tethering LMO2 to synthetic DNA sequences converts them into replication origins; lowering LMO2 in erythroid progenitors delays G1-S progression, while ectopic expression in thymocytes drives DNA replication and cell cycle entry.\",\n      \"method\": \"Co-immunoprecipitation with replication enzymes, synthetic origin tethering assay, BrdU incorporation, ChIP at replication origins\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro reconstitution with replication enzymes, tethering assay, multiple orthogonal methods\",\n      \"pmids\": [\"26764384\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"In basal-type breast cancer cells, LMO2 localizes predominantly to the cytoplasm where it interacts with cofilin1 to regulate actin cytoskeleton dynamics, promoting tumor cell migration and invasion.\",\n      \"method\": \"Subcellular fractionation, co-immunoprecipitation with cofilin1, migration/invasion assays, SCID mouse metastasis model\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — single Co-IP with functional invasion assay, single lab\",\n      \"pmids\": [\"27880729\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Lmo2 directly regulates Sphk1 gene expression in endothelial cells by binding to the Sphk1 promoter (shown by ChIP-PCR); Lmo2 knockdown reduces Sphk1 expression and impairs endothelial cell migration and intersegmental vessel formation; Sphk1 mRNA rescues the Lmo2 KD phenotype.\",\n      \"method\": \"ChIP-PCR, morpholino knockdown in zebrafish, scratch assay, aortic ring assay, mRNA rescue\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP at specific promoter plus in vivo loss-of-function with rescue\",\n      \"pmids\": [\"28775072\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Recurrent intronic mutations in LMO2 in T-ALL create de novo MYB, ETS1, or RUNX1 binding sites that activate a neomorphic promoter, causing monoallelic LMO2 overexpression; CRISPR/Cas9 disruption of the mutant allele markedly downregulates LMO2 expression.\",\n      \"method\": \"5'-capped RNA transcript mapping, CRISPR/Cas9 allele-specific disruption, transcription factor binding site analysis\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — CRISPR causality experiment with molecular mechanism established\",\n      \"pmids\": [\"28270453\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"LMO2 is required for TAL1 DNA-binding activity at hematopoietic regulatory elements; in Lmo2-/- cells, target site recognition of TAL1 is impaired genome-wide, and LMO2 positions the TAL1/LMO2/LDB1 complex at regulatory elements important for the haematopoietic developmental program.\",\n      \"method\": \"Lmo2-/- ES cell differentiation, genome-wide ChIP-seq for TAL1 and LMO2, comparison with Tal1-/- cells\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genome-wide ChIP-seq in matched KO cells, mechanistic interpretation supported by multiple datasets\",\n      \"pmids\": [\"28973433\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"LMO2 inhibits BRCA1 recruitment to DNA double-strand breaks by interacting with 53BP1 during repair, rendering LMO2-positive DLBCL and T-ALL cells deficient in homologous recombination and sensitive to PARP inhibitors.\",\n      \"method\": \"Co-immunoprecipitation of LMO2 with 53BP1, BRCA1 recruitment assay at DSB sites, HR functional assay, PARP inhibitor sensitivity\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP with mechanistic HR assay and pharmacological validation\",\n      \"pmids\": [\"31447348\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"LMO2 is deacetylated on lysine 74 and 78 by the NAMPT/SIRT2 pathway; deacetylation enables LMO2 to interact with LDB1 and activate the TAL1 complex; NAMPT or SIRT2 inhibition suppresses T-ALL cell growth by diminishing LMO2 deacetylation.\",\n      \"method\": \"Mass spectrometry of LMO2 acetylation sites, SIRT2 deacetylase assay, Co-IP of deacetylated LMO2 with LDB1, NAMPT/SIRT2 inhibitor treatment, zebrafish blood formation assay\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — PTM identified by MS, enzymatic validation, interaction consequence, in vivo functional data\",\n      \"pmids\": [\"31366618\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Lmo2 directly binds the prdm16 promoter in endothelial cells (shown by ChIP-PCR) and regulates prdm16 transcription; lmo2 loss-of-function in zebrafish reduces prdm16 expression and impairs angiogenesis, establishing an Lmo2-Prdm16 axis in angiogenesis.\",\n      \"method\": \"ChIP-PCR, lmo2 loss-of-function zebrafish, RNA-seq comparison of endothelial cell populations\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP at specific promoter with in vivo loss-of-function, single lab\",\n      \"pmids\": [\"34330825\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Human Bex2 specifically interacts with LMO2 (shown by GST pull-down and co-immunoprecipitation) and forms part of a DNA-binding complex with LMO2, enhancing LMO2 transcriptional activity; LMO2 also interacts with neuronal bHLH protein NSCL2 and upregulates NSCL2-dependent transcription.\",\n      \"method\": \"GST pull-down, co-immunoprecipitation, EMSA, mammalian two-hybrid, reporter assay\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple interaction methods with functional reporter data, single lab\",\n      \"pmids\": [\"16314316\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"The N-terminal portions of RBTN1 and RBTN2 (LMO2) support transcriptional transactivation in transfection assays; the NH2-terminal 27 amino acids of RBTN2 are sufficient for transactivation in yeast, and RBTN2 forms homodimers.\",\n      \"method\": \"Transfection reporter assays, yeast two-hybrid and transactivation assay\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional domain mapping with reporter assays\",\n      \"pmids\": [\"7731680\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"LMO2 directly assembles TAL1-E47/LYL1 dimers with GATA2 at the ANG-2 promoter in endothelial cells; ChIP demonstrated occupancy of TAL1, LYL1, LMO2, and GATA2 at an E-box/GATA composite element; knockdown of any factor reduces ANG-2 expression.\",\n      \"method\": \"ChIP, siRNA knockdown, promoter reporter assay, co-immunoprecipitation\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct ChIP of LMO2 and partners at endogenous promoter with loss-of-function validation\",\n      \"pmids\": [\"22792348\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"LMO2 is a LIM-only scaffolding protein that functions as a conformationally flexible bridge within multiprotein transcriptional complexes—including TAL1/SCL, LDB1, GATA1/2, and E-proteins—to regulate hematopoietic and endothelial gene expression programs; its activity is modulated by SIRT2-mediated deacetylation (enabling LDB1 interaction), proteasomal stabilization via SCL binding, and miR-223-mediated translational repression, while in addition to its transcriptional role LMO2 directly promotes DNA replication by interacting with POLD1, PRIM1, and MCM6 at origins, and in DLBCL it inhibits homologous recombination by sequestering 53BP1 away from BRCA1 at DSBs.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"LMO2 is a LIM-only transcriptional scaffolding protein essential for definitive hematopoiesis, erythropoiesis, and angiogenic vascular remodeling. It functions as an intrinsically disordered bridge that is stabilized upon binding LDB1 via its LIM domains; this interaction is regulated by SIRT2-mediated deacetylation of Lys74/78 and by SCL/TAL1 binding, which prevents proteasomal degradation [PMID:21076045, PMID:31366618, PMID:17878155]. LMO2 nucleates distinct multiprotein DNA-binding complexes—containing TAL1 or LYL1 with E-proteins, GATA factors, and LDB1—at E-box/GATA composite elements to activate hematopoietic (e.g., HHEX) and endothelial (e.g., ANG-2, NRP2, SPHK1) gene programs, and is required genome-wide for TAL1 chromatin occupancy [PMID:28973433, PMID:22792348, PMID:24465765]. Beyond transcription, LMO2 directly promotes DNA replication by interacting with POLD1, PRIM1, and MCM6 at origins [PMID:26764384], and in DLBCL it impairs homologous recombination by sequestering 53BP1 from BRCA1 at double-strand breaks, conferring PARP-inhibitor sensitivity [PMID:31447348].\",\n  \"teleology\": [\n    {\n      \"year\": 1994,\n      \"claim\": \"Loss-of-function established LMO2 as indispensable for primitive erythropoiesis, answering whether this T-ALL translocation target had a normal developmental role.\",\n      \"evidence\": \"Homologous recombination knockout in mice causing embryonic lethal failure of yolk sac erythropoiesis\",\n      \"pmids\": [\"8033210\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of action (transcription factor? cofactor?) unknown\", \"Role in definitive hematopoiesis not yet tested\", \"Downstream targets unidentified\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Identification of the LMO2–TAL1 physical complex in erythroid cells provided the first evidence that two T-ALL oncogenes cooperate through direct protein interaction in normal hematopoiesis.\",\n      \"evidence\": \"Reciprocal co-immunoprecipitation in erythroid cell lines\",\n      \"pmids\": [\"8078932\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry and additional complex members unknown\", \"DNA binding of the complex not demonstrated\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Discovery that LMO2 bridges TAL1 to GATA1/GATA2 and E47 defined the multiprotein architecture through which LMO2 links hematopoietic transcription factors on DNA.\",\n      \"evidence\": \"In vitro pull-down, co-IP, and mammalian two-hybrid\",\n      \"pmids\": [\"7568177\", \"9209374\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"3D structure of the complex unknown\", \"Direct DNA target genes not identified\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Demonstration that LMO2 and TAL1 synergize to accelerate T-cell leukemia in vivo established the oncogenic mechanism as a physical protein dimer in thymocytes.\",\n      \"evidence\": \"Double-transgenic mice with protein dimerization detection and tumor latency comparison\",\n      \"pmids\": [\"8605871\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the critical partner in T-ALL (TAL1 vs. LYL1) not resolved\", \"Downstream oncogenic transcriptional targets unknown\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Identification of LDB1 as a stable partner of LMO2 added the fourth core subunit to the hematopoietic complex and showed that this complex maintains erythroid precursors in an immature state.\",\n      \"evidence\": \"Co-IP in murine erythroleukemia cells, EMSA, and forced expression in proerythroblasts\",\n      \"pmids\": [\"9391090\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of LMO2–LDB1 interaction unknown\", \"How complex stoichiometry is regulated unclear\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Chimeric mouse experiments proved LMO2 is required for all adult hematopoietic lineages, not just primitive erythropoiesis, and that this requirement could be rescued by transgene re-expression.\",\n      \"evidence\": \"Lmo2-null ES cell chimeras with retroviral rescue\",\n      \"pmids\": [\"9520463\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether LMO2 acts at the level of HSC self-renewal or differentiation unclear\", \"Cell-type-specific complex composition not explored\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Establishing that LMO2 is required for angiogenic remodeling but not de novo vasculogenesis extended its function beyond blood to endothelium.\",\n      \"evidence\": \"Lmo2-null ES cell chimeras with vascular phenotyping\",\n      \"pmids\": [\"10618416\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endothelial target genes of LMO2 unknown\", \"Whether the same TAL1-containing complex operates in endothelium unclear\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"NMR structure of LMO2:LDB1-LID provided the first atomic-resolution view of how LDB1 binds as an extended strand to the LIM1 domain, revealing the structural basis of the core scaffolding interaction.\",\n      \"evidence\": \"NMR structure determination\",\n      \"pmids\": [\"12727888\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full pentameric complex structure on DNA not available\", \"Conformational dynamics between LIM domains uncharacterized\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"The crystal structure of LMO2:LDB1 revealed that LMO2 is largely intrinsically disordered and requires LDB1 to adopt a defined conformation, with a flexible hinge between LIM domains critical for TAL1 binding and in vivo function.\",\n      \"evidence\": \"X-ray crystallography at 2.4 Å with mutant rescue in zebrafish\",\n      \"pmids\": [\"21076045\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Hinge dynamics in solution not measured\", \"How disorder-to-order transition is regulated in the cell unknown\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Structural demonstration that GATA1 simultaneously contacts LMO2 and FOG1 resolved how FOG1-dependent and TAL1/LMO2-dependent gene regulation can co-occur at the same GATA1-bound sites.\",\n      \"evidence\": \"NMR structure, EMSA, and pulldown assays\",\n      \"pmids\": [\"21844373\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Genome-wide co-occupancy of FOG1 and LMO2 complex not mapped\", \"Whether this dual binding mode operates at all GATA1 targets unclear\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Identification of an LMO2–TAL1/LYL1–GATA2 complex at the ANG-2 promoter in endothelial cells demonstrated a direct endothelial transcriptional target and showed the hematopoietic-type complex operates in vasculature.\",\n      \"evidence\": \"ChIP at endogenous ANG-2 promoter with siRNA knockdown of each factor\",\n      \"pmids\": [\"22792348\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Genome-wide endothelial target repertoire not defined\", \"Complex composition may differ across vascular beds\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"The crystal structure of the full (SCL:E47)bHLH:LMO2:LDB1 complex on DNA revealed that LMO2 allosterically strengthens the SCL:E47 heterodimer while rotating E47 to weaken its DNA grip, explaining how LMO2 shifts DNA-binding specificity.\",\n      \"evidence\": \"X-ray crystallography of multiprotein–DNA complex with biochemical validation\",\n      \"pmids\": [\"23831025\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether this allosteric mechanism applies to LYL1-containing complexes unknown\", \"In vivo consequences of the rotational shift not directly tested\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Genetic epistasis showed that LYL1, not SCL/TAL1, is the obligate bHLH partner recruited by LMO2 to drive T-cell leukemia, resolving a longstanding ambiguity about the oncogenic complex composition.\",\n      \"evidence\": \"Conditional knockout of Scl or Lyl1 in Lmo2-transgenic mice with transplantation and gene expression profiling\",\n      \"pmids\": [\"23926305\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How LMO2 selects LYL1 over TAL1 in thymocytes not mechanistically explained\", \"Direct LYL1:LMO2 binding affinity not measured\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Discovery that LMO2 interacts with replication machinery (POLD1, PRIM1, MCM6) and can convert arbitrary DNA into a replication origin revealed an unexpected non-transcriptional function in DNA replication initiation.\",\n      \"evidence\": \"Co-IP with replication enzymes, synthetic origin tethering assay, BrdU incorporation, ChIP at origins\",\n      \"pmids\": [\"26764384\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether replication function is separable from transcriptional function in vivo unclear\", \"Structural basis of LMO2–replication machinery interaction unknown\", \"Relevance to normal vs. oncogenic replication programs not delineated\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Genome-wide ChIP-seq in Lmo2-knockout cells proved that LMO2 is required for TAL1 chromatin occupancy at hematopoietic regulatory elements, establishing LMO2 as a positioning factor rather than a passive scaffold.\",\n      \"evidence\": \"Lmo2−/− ES cell differentiation with genome-wide TAL1 and LMO2 ChIP-seq\",\n      \"pmids\": [\"28973433\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which LMO2 enables TAL1 DNA binding (chromatin opening vs. direct tethering) not resolved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"LMO2 was shown to impair homologous recombination by sequestering 53BP1 from BRCA1 at DSBs, providing a non-transcriptional mechanism for its role in DLBCL biology and creating a therapeutic vulnerability to PARP inhibitors.\",\n      \"evidence\": \"Co-IP of LMO2 with 53BP1, BRCA1 recruitment assay, HR functional assay, PARP inhibitor sensitivity in DLBCL and T-ALL cells\",\n      \"pmids\": [\"31447348\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether the LMO2–53BP1 interaction is direct or bridged unknown\", \"Structural details of the interaction not available\", \"Clinical efficacy of PARP inhibitors in LMO2-expressing tumors not established\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identification of SIRT2-mediated deacetylation of LMO2 at K74/K78 as a prerequisite for LDB1 binding revealed the first post-translational regulatory switch controlling LMO2 complex assembly.\",\n      \"evidence\": \"Mass spectrometry acetylation mapping, SIRT2 deacetylase assay, Co-IP of deacetylated LMO2 with LDB1, NAMPT/SIRT2 inhibitor treatment, zebrafish assay\",\n      \"pmids\": [\"31366618\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Which acetyltransferase acetylates LMO2 not identified\", \"Whether acetylation state also regulates replication or DNA repair functions unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How LMO2's transcriptional, replication-initiating, and DNA-repair-inhibitory functions are coordinated or partitioned across cell types and cell-cycle phases remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No integrative study has tested all three functions in the same cell system\", \"Structural basis for LMO2 interaction with replication machinery and 53BP1 lacking\", \"Whether LMO2 post-translational modifications differentially regulate each function is untested\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [2, 4, 10, 18, 23]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [2, 17, 32, 37, 38]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [1, 6, 18, 32]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [0, 5, 7, 8]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [2, 17, 32, 38]},\n      {\"term_id\": \"R-HSA-69306\", \"supporting_discovery_ids\": [28]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [33]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [3, 24, 31, 33]}\n    ],\n    \"complexes\": [\n      \"TAL1/SCL–E47–LMO2–LDB1 complex\",\n      \"LYL1–E2A–LMO2–LDB1 complex\",\n      \"GATA1/2–LMO2–TAL1–E47–LDB1 complex\"\n    ],\n    \"partners\": [\n      \"TAL1\",\n      \"LDB1\",\n      \"GATA1\",\n      \"GATA2\",\n      \"LYL1\",\n      \"53BP1\",\n      \"POLD1\",\n      \"PRIM1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}